Literature DB >> 29383700

Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma.

Huijuan Jiang1,2, Tint Lwin1, Xiaohong Zhao1, Yuan Ren1, Grace Li1, Lynn Moscinski1,3, Bijal Shah4, Jianguo Tao1,3.   

Abstract

Entities:  

Keywords:  BCL2; PI3K/AKT; mantle cell lymphoma

Mesh：

Substances：

Year:  2018        PMID： 29383700      PMCID： PMC6066460          DOI： 10.1111/bjh.15079

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  10 in total

Review 1.  Targeting the B-cell lymphoma/leukemia 2 family in cancer.

Authors:  Matthew S Davids; Anthony Letai
Journal:  J Clin Oncol       Date:  2012-05-29       Impact factor: 44.544

2.  An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells.

Authors:  Ariosto Silva; Timothy Jacobson; Mark Meads; Allison Distler; Kenneth Shain
Journal:  J Vis Exp       Date:  2015-07-15       Impact factor: 1.355

3.  ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets.

Authors:  Meike Vogler; David Dinsdale; Martin J S Dyer; Gerald M Cohen
Journal:  Br J Haematol       Date:  2013-07-04       Impact factor: 6.998

Review 4.  Mantle cell lymphoma: evolving management strategies.

Authors:  Elias Campo; Simon Rule
Journal:  Blood       Date:  2014-12-11       Impact factor: 22.113

5.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Authors:  Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

6.  Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.

Authors:  Baohua Sun; Bhavin Shah; Warren Fiskus; Jun Qi; Kimal Rajapakshe; Cristian Coarfa; Li Li; Santhana G T Devaraj; Sunil Sharma; Liang Zhang; Michael L Wang; Dyana T Saenz; Stephanie Krieger; James E Bradner; Kapil N Bhalla
Journal:  Blood       Date:  2015-08-07       Impact factor: 22.113

7.  BH3 profiling in whole cells by fluorimeter or FACS.

Authors:  Jeremy Ryan; Anthony Letai
Journal:  Methods       Date:  2013-04-20       Impact factor: 3.608

Review 8.  The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies.

Authors:  K H Shain; J Tao
Journal:  Oncogene       Date:  2013-09-16       Impact factor: 9.867

9.  Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma.

Authors:  Xiaohong Zhao; Tint Lwin; Ariosto Silva; Bijal Shah; Jiangchuan Tao; Bin Fang; Liang Zhang; Kai Fu; Chengfeng Bi; Jiannong Li; Huijuan Jiang; Mark B Meads; Timothy Jacobson; Maria Silva; Allison Distler; Lancia Darville; Ling Zhang; Ying Han; Dmitri Rebatchouk; Maurizio Di Liberto; Lynn C Moscinski; John M Koomen; William S Dalton; Kenneth H Shain; Michael Wang; Eduardo Sotomayor; Jianguo Tao
Journal:  Nat Commun       Date:  2017-04-18       Impact factor: 14.919

10.  The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma.

Authors:  C Touzeau; C Dousset; S Le Gouill; D Sampath; J D Leverson; A J Souers; S Maïga; M C Béné; P Moreau; C Pellat-Deceunynck; M Amiot
Journal:  Leukemia       Date:  2013-07-17       Impact factor: 11.528
  10 in total
  5 in total

1.  PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas.

Authors:  Yuan Ren; Chengfeng Bi; Xiaohong Zhao; Tint Lwin; Cheng Wang; Ji Yuan; Ariosto S Silva; Bijal D Shah; Bin Fang; Tao Li; John M Koomen; Huijuan Jiang; Julio C Chavez; Lan V Pham; Praneeth R Sudalagunta; Lixin Wan; Xuefeng Wang; William S Dalton; Lynn C Moscinski; Kenneth H Shain; Julie Vose; John L Cleveland; Eduardo M Sotomayor; Kai Fu; Jianguo Tao
Journal:  J Clin Invest       Date:  2018-11-05       Impact factor: 14.808

Review 2.  Mitochondria in cancer metabolism, an organelle whose time has come?

Authors:  Rebecca G Anderson; Lais P Ghiraldeli; Timothy S Pardee
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-05-26       Impact factor: 10.680

3.  MCL-1 dependency as a novel vulnerability for aggressive B cell lymphomas.

Authors:  Michelle Y Wang; Tao Li; Yuan Ren; Bijal D Shah; Tint Lwin; Jing Gao; Kenneth H Shain; Wei Zhang; Xiaohong Zhao; Jianguo Tao
Journal:  Blood Cancer J       Date:  2021-01-14       Impact factor: 11.037

4.  Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma.

Authors:  Xiaohong Zhao; Michelle Y Wang; Huijuan Jiang; Tint Lwin; Paul M Park; Jing Gao; Mark B Meads; Yuan Ren; Tao Li; Jiao Sun; Naima Ahmed Fahmi; Satishkumar Singh; Lalit Sehgal; Xuefeng Wang; Ariosto S Silva; Eduardo M Sotomayor; Kenneth H Shain; John L Cleveland; Michael Wang; Wei Zhang; Jun Qi; Bijal D Shah; Jianguo Tao
Journal:  Cell Rep       Date:  2021-03-16       Impact factor: 9.423

Review 5.  Programmed cell death, redox imbalance, and cancer therapeutics.

Authors:  Xiaofeng Dai; Danjun Wang; Jianying Zhang
Journal:  Apoptosis       Date:  2021-07-08       Impact factor: 4.677
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.